Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK1070806 in Moderate-to-Severe Crohn's Disease
NCT03681067Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Feb 2019
- Primary completion
- Jun 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of aletekitug in Crohn's disease, sponsored by University of Birmingham. Started Feb 2019; status: completed.
02
Drugs
aletekitug
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03681067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03681067.